Abstract:Cathepsin K (CK), a lysosomal cysteine protease, is highly expressed in mature osteoclasts and degrades type 1 collagen. Odanacatib (ODN) is a selective and reversible CK inhibitor that inhibits bone loss in preclinical and clinical studies. Although an antiresorptive, ODN does not suppress bone formation, which led us to hypothesize that ODN may display restorative effect on the osteopenic bones. In a curative study, skeletally mature New Zealand rabbits were ovarectomized (OVX) and after induction of bone loss were given a steady-state exposure of ODN (9 mM/d) for 14 weeks. Sham-operated and OVX rabbits treated with alendronate (ALD), 17b-estradiol (E2), or parathyroid hormone (PTH) served as various controls. Efficacy was evaluated by assessing bone mineral density (BMD), bone microarchitecture (using micro-computed tomography), fluorescent labeling of bone, and biomechanical strength. Skeletal Ca/P ratio was measured by scanning electron microscopy (SEM) with X-ray microanalysis, crystallinity by X-ray diffraction, and bone mineral density distribution (tissue mineralization) by backscattered SEM. Between the sham and ODN-treated osteopenic groups, lumbar and femur metaphyseal BMD, Ca/P ratio, trabecular microstructure and geometric indices, vertebral compressive strength, trabecular lining cells, cortical parameters (femoral area and thickness and periosteal deposition), and serum P1NP were largely comparable. Skeletal improvements in ALD-treated or E2-treated groups fell significantly short of the sham/ODN/PTH group. However, the ODN group displayed reduced ductility and enhanced brittleness of central femur, which might have been contributed by higher crytallinity and tissue mineralization. Rabbit bone marrow stromal cells expressed CK and when treated with ODN displayed increased formation of mineralized nodules and decreased apoptosis in serum-deficient medium compared with control. In vivo, ODN did not suppress remodeling but inhibited osteoclast activity more than ALD. Taken together, we show that ODN reverses BMD, skeletal architecture, and compressive strength in osteopenic rabbits; however, it increases crystallinity and tissue mineralization, thus leading to increased cortical bone brittleness.

Azanitrile Cathepsin K Inhibitors: Effects on Cell Toxicity, Osteoblast-Induced Mineralization and Osteoclast-Mediated Bone Resorption

Real-time analysis of osteoclast resorption and fusion dynamics in response to bone resorption inhibitors

Inhibitory Effects of 2N1HIA (2-(3-(2-fluoro-4-methoxyphenyl)-6-oxo-1(6h)-pyridazinyl)-n-1h-indol-5-ylacetamide) on Osteoclast Differentiation Via Suppressing Cathepsin K Expression.

A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture

Cathepsin K: The Action in and Beyond Bone

Inhibition of cysteine protease disturbs the topological relationship between bone resorption and formation in vitro

Natural Inhibitors Targeting Osteoclast-Mediated Bone Resorption

Discovery of a New Class of Cathepsin K Inhibitors in Rhizoma Drynariae As Potential Candidates for the Treatment of Osteoporosis.

Synthesis and Biological Evaluation of Novel Piperidine-3-Carboxamide Derivatives as Anti-Osteoporosis Agents Targeting Cathepsin K

Integrated machine learning-based virtual screening and biological evaluation for identification of potential inhibitors against cathepsin K

Study of a Novel Antiosteoporosis Screening Model Targeted on Cathepsin K.

Lead optimization of cathepsin K inhibitors for the treatment of Osteoarthritis

Inhibition of cathepsin K promotes osseointegration of titanium implants in ovariectomised rats

Advances in Cathepsin K inhibitor Odanacatib in treatment of osteoporosis

Discovery of Selective Covalent Cathepsin K Inhibitors Containing Novel 4-Cyanopyrimidine Warhead Based on Quantum Chemical Calculations and Binding Mode Analysis

Odanacatib Restores Trabecular Bone of Skeletally Mature Female Rabbits With Osteopenia but Induces Brittleness of Cortical Bone: A Comparative Study of the Investigational Drug With PTH, Estrogen, and Alendronate

Novel selective proline-based peptidomimetics for human cathepsin K inhibition

Dual targeting of salt inducible kinases and CSF1R uncouples bone formation and bone resorption

NVP-BHG712 against postmenopausal osteoporosis in mice by targeting Cathepsin K

Osteogenic Effects Of A Potent Src-Over-Abl-Selective Kinase Inhibitor In The Mouse

Increased fracture callus mineralization and strength in cathepsin K knockout mice